UroGen Pharma (URGN) Stock Forecast & Price Target
UroGen Pharma (URGN) Analyst Ratings
Bulls say
UroGen Pharma Ltd has demonstrated substantial financial growth, with net product revenue increasing by 9% year-over-year to reach $90.4 million for 2024, driven primarily by strong demand for its flagship product, JELMYTO, which alone saw revenue rise to $24.6 million in Q4 2024. The company’s projections indicate a significant upward trajectory, forecasting top-line sales to grow to $114.1 million in 2025 and further to $338.8 million by 2026. Additionally, strong clinical data, particularly the positive 18-month duration of response of 80.6% for UGN-102 in the Phase 3 ENVISION trial, positions UroGen favorably for a potential commercial launch and addresses a sizable market opportunity exceeding $5 billion.
Bears say
UroGen Pharma experienced a significant financial setback, reporting a net loss of $2.96 per share for the full year 2024, which indicates challenges in achieving profitability. The company faced a widening net loss of $37.5 million in Q4, up from $26 million in the previous year, contributing to a total annual net loss of $126.9 million. Key risks include the potential inability to penetrate the market as projected due to increased competition and pricing pressures, along with uncertainties regarding the successful transition to upcoming product candidates and overall clinical trial outcomes.
This aggregate rating is based on analysts' research of UroGen Pharma and is not a guaranteed prediction by Public.com or investment advice.
UroGen Pharma (URGN) Analyst Forecast & Price Prediction
Start investing in UroGen Pharma (URGN)
Order type
Buy in
Order amount
Est. shares
0 shares